JMJD2D (KDM4D) Chemiluminescent Assay Kit
The JMJD2D (KDM4D) Chemiluminescent Assay Kit is an ELISA (enzyme-linked immunosorbent assay)-based assay designed to measure the demethylase activity of JMJD2D (Jumonji domain-containing protein 2D) for screening and profiling applications. The JMJD2D (KDM4D) assay kit comes in a convenient 96-well format, with enough purified recombinant JMJD2D enzyme (amino acids 2-354), pre-coated plate with histone substrate, all the reagents necessary for assay detection and blocking buffer for 96 enzyme reactions.
- TBST Buffer (1x Tris-buffered saline, pH 8, containing 0.05% Tween-20)
- Luminometer or microplate reader capable of reading chemiluminescence
- Adjustable micropipettor and sterile tips
- Rotating or rocker platform
| Catalog # | Name | Amount | Storage |
| 50117 | JMJD2D (KDM4D), GST-Tag* | 40 µg | -80°C |
| 52140E | Primary Antibody 5 | 12.5 µl | -80°C |
| 52130H | Secondary HRP-Labeled Antibody 1 | 10 µl | -80°C |
| 4x JMJD2D Direct Assay Buffer | 3 x 1 ml | -80°C | |
| 52100 | Blocking Buffer 4 | 50 ml | +4°C |
| HRP chemiluminescent substrate A | 6 ml | Room Temp | |
| HRP chemiluminescent substrate B | 6 ml | Room Temp | |
| White plate pre-coated with Histone-Substrate | 1 | Room Temp |
*The concentration of the protein is lot-specific and will be indicated on the tube.
JMJD2D (Jumonji domain -containing protein 2D), also known as KDM4D, belongs to the JMJD2 subfamily of JMJD histone lysine demethylase proteins. It is involved in demethylating H3K9me2/3 and H1.4K26, participating in DNA replication and repair and transcription. It acts as an epigenetic regulator in androgen-receptor activation, inflammation, and tumor progression. JMJD2D has been linked to liver, colorectal, and pancreatic cancer. JMJD2D acts on the β-catenin pathway, by demethylating β-catenin target gene promoters and bringing β-catenin in proximity to them. Amongst other roles, it also participates in promoting glycolysis in cancer cells, likely by acting on the HIF1α (hypoxia inducible factor 1 alpha) pathway. The use of JMJD2D inhibitors is an area of interest that requires further development, and the development of active inhibitors will be beneficial in cancer therapy.
Manni W., et al., 2022 Signal Transduct Target Ther 7:304.
Chen Q., et al., 2022 Cancers (Basel) 14(12):2841.
Powered by Bioz
San Diego, CA 92121
858-202-1401
Products are for Research Use Only
COMPANY
Copyright © 2024
BPS Bioscience, Inc.
All rights reserved.
Diagrams on this website are created with BioRender.com.